Partnerships are foundational to who we are at invoX. We foster strong relationships across the globe that enable us to leverage our differentiated technology platform with external partners for the benefit of patients.
Our cutting-edge fully industrialised SMI platform technology, along with our team of experts with deep industry experience can support out partners, to deliver innovative inhalation products for life cycle management of existing products. Our portfolio of device solutions can be customised to meet the needs of our partners. To date, we have entered multiple international partnerships to advance our pipeline of generic and innovative programs for the benefit of patients.
Our Partnering Model
We have a flexible approach to partnering that accelerates the delivery of medicines to patients. We are open to co-development partnerships that enable partners to deliver their medicines leveraging our SMI platform or to licence on our internal pipeline.
If you would like to discuss opportunities to partner with invoX, please contact BD@invoxpharma.com.
Areas of interest
Technology Platform Partnering
Co-development partnerships leveraging our SMI platform with partners developing late stage / approved medicines for patients with respiratory disease which would benefit from the greener footprint and deep lung delivery of our proprietary SMI platform. This can include generic products, as well as innovative small molecule, peptide, biologic and LNP encapsulated oligonucleotides.
Diseases of particular interest include: asthma, COPD, fibrotic lung diseases including IPF and Cystic Fibrosis, as well as select central nervous system indications.
Complementary Assets / Technologies
Novel assets and technologies from academia or industry which are complementary to our existing pipeline and platforms.
How we work
Trusted: Successful collaboration starts with transparent communication, and we build partnerships that are based on mutual trust and a shared vision for success.
Innovative: We are open to explore new ways of doing things, including flexible and innovative partnership structures that unlock new avenues for research.
Open: Patient needs are not defined by borders, so neither are we. We reach out across the globe to all partners, from academic institutions to biotech and larger pharmaceutical companies, to build partnerships for the benefit of patients.